Cancer Prognosis and miRNA

Faten Alnoaimi; Mehmet Özaslan

doi:10.55549/zbs.1680820

Cancer Prognosis and miRNA

Abstract

The micro ribonucleic acids are commonly referred to as MicroRNAs, miRNAs or μRNA. These micro-nucleic acids are very short and single-stranded RNA molecules composed by 19 to 25 nucleotides. miRNAs play an important regulatory role in the cells of many organisms including humans, animals, and plants. miRNAs were discovered in 1993 and the role and mechanism of action of these molecules is still under investigation. Recently, it has been confirmed that the non-coding miRNAs play an essential role in gene regulation. Considering the role of miRNAs in many biological and pathological reactions and mechanisms, especially cancer, scientific interest in these molecules is increasing as these molecules are believed to hold great promise as a therapeutic approach. The discovery of miRNAs is considered as the beginning of a new age in molecular biology. This article will provide an outlook on miRNAs, the stages of their biogenesis, types of miRNAs and their role in cancer initiation and progression. Therefore, the aim of this research is to identify the biological mechanisms by which miRNAs can influence cellular functions that are disrupted in the initiation and progression of cancer. In addition, this research also aims to demonstrate the potential of utilizing miRNAs in the diagnosis and therapy of different types of cancer.

Keywords

microRNA, miRNA, μRNA, TSmiRNAs, OncomiRNAs, Cancer

Supporting Institution

No support was received for this study

Ethical Statement

This paper does not require ethics committee approval

References

Ali Syeda, Z., Langden, S. S. S., Munkhzul, C., Lee, M., and Song, S. J. (2020). Regulatory mechanism of MicroRNA expression in cancer. International journal of molecular sciences, 21(5), 1723.‏ doi: 10.3390/ijms21051723
Amaral, F. C., Torres, N., Saggioro, F., Neder, L., Machado, H. R., Silva Jr, W. A. and Castro, M. (2009). MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. The Journal of Clinical Endocrinology & Metabolism, 94(1), 320-323. 10.1210/jc.2008-1451
Bao, C., Chen, J., Chen, D., Lu, Y., Lou, W., Ding, B., Xu, L., and Fan, W. (2020). MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1. Cell Death & Disease, 11(8), 3166–3177. 10.1111/jcmm.14171
Bašová, P., Pešta, M., Sochor, M., and Stopka, T. (2017). Prediction potential of serum mir-155 and mir-24 for relapsing early breast cancer. Int. J. Mol. Sci., 18, 1–10. 10.3390/ijms18102116
Breunig, C., Pahl, J., Küblbeck, M., Miller, M., Antonelli, D., Erdem, N., and Wiemann, S. (2017). MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell death & disease, 8(8), e2973-e2973. 10.1038/cddis.2017.364
Calin, G. A., Cimmino, A., Fabbri, M., Ferracin, M., Wojcik, S. E., Shimizu, M. and Alder, H. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences, 105(13), 5166-5171. https://doi.org/10.1073/pnas.080012110
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E. and Rassenti, L. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the national academy of sciences, 99(24), 15524-15529. 10.1073/pnas.242606799
Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E. and Iuliano, R. (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New England Journal of Medicine, 353(17), 1793-1801. 10.1056/NEJMoa050995
Cameron, J. E., Yin, Q., Fewell, C., Lacey, M., McBride, J., Wang, X. and Flemington, E. K. (2008). Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. Journal of virology, 82(4), 1946-1958. 10.1128/JVI.02136-07
Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in control of gene expression: an overview of nuclear functions. International journal of molecular sciences, 17(10), 1-17. 10.3390/ijms17101712

Chen, J., Wang, B. C., and Tang, J. H. (2012). Clinical significance of micoRNA-155 expression in human breast cancer. Journal of surgical oncology, 106(3), 260-266.
Chen, P., Xu, W., Luo, Y., Zhang, Y., He, Y., Yang, S., and Yuan, Z. (2017). MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. OncoTargets and therapy, 6(10), 1423-1431. 10.2147/OTT.S118366
Corcoran, C., Rani, S., Breslin, S., Gogarty, M., Ghobrial, I. M., Crown, J., O'Driscoll, L. (2014). miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Molecular Cancer, 234(3), 2880–2894. 10.1186/1476-4598-13-71
Dharanija, M., Katarina, C., Burwinkel, B., and Rongxi, Y. (2013). Cancer diagnosis andprognosis decoded by blood-based circulating microRNA signatures. Front.Genet, 4, 116–127. 10.3389/fgene.2013.00116
Dinçer, B. C. (2023). Investigation of miRNA molecules as biomarkers in the diagnosis of breast cancer. (Master's Thesis) İstanbul University the Institute of Health Sciences, İstanbul, Türkiye.
Elnaggar, G. N., El-Hifnawi, N. M., Ismail, A., Yahia, M., Elshimy, R. A. A. (2021). Micro RNA-148a targets Bcl-2 in patients with non-small cell lung cancer. Asian Pacific J Cancer Prev, 22(6), 1949–1955. 10.31557/ APJCP.2021.22.6.1949 Elton, T. S., Selemon, H., Elton, S. M., and Parinandi, N. L. (2012). Regulation of the MIR155 host gene in physiological and pathological processes. Gene., 18, 1–63. 10.1016/j.gene.2012.12.009
Feng, H., Ge, F., Du, L., Zhang, Z., and Liu, D. (2019). MiR - 34b - 3p Represses Cell Proliferation, Cell Cycle Progression and Cell Apoptosis in Non - Small -Cell Lung Cancer (NSCLC) by Targeting CDK4. J Cell Mol Med, 23(8), 5282–5291. 10.1111/jcmm.14404
Friedländer, M. R., Lizano, E., J S Houben, A. J. S., Bezdan, D., Báñez-Coronel, M., Kudla, G., Mateu-Huertas, E., Kagerbauer, B., González, J., Chen, K. C., LeProust, E. M., Martí, E., and Estivill, X. (2014). Evidence for the biogenesis of more than 1,000 novel human microRNAs. Genome biology, 15, 1-17. 10.1186/gb-2014-15-4-r57
Fu, X., Yin, Y., Zhang, M., Peng, F., Shi, Y., Liu, Y., Tan, Y., Zhao, Z., Yin, X., Song, J., Ke, G., and Zhang, X. (2021). Size-selective DNA nanocage-based activatable CRISPR-Cas12a for sensitive and accurate detection of mature microRNA. Chemical Communications, 57(26), 3291–3294. 10.1039/d1cc00178g
Garrido-Cano, I., Pattanayak, B., Adam-Artigues, A., Lameirinhas, A., Torres-Ruiz, S., Tormo, E., Cervera, R., and Eroles, P. (2022). MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer and Metastasis Reviews, 41, 77-105. https://doi.org/10.1007/s10555-021-09992-0
Gomez, G. G., Wykosky, J., Zanca, C., Furnari, F. B., and Cavenee, W. K. (2013). Therapeutic resistance in cancer: MicroRNA regulation of EGFR signaling networks. Cancer Biology & Medicine, 10(4), 192–205. 10.7497/j.issn.2095-3941.2013.04.003
Gonzalez-Alegre, P. (2007). Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacology & therapeutics, 114(1), 34-55. 10.1016/j.pharmthera.2007.01.003
Grace, L., Phoebe, M., and Jemmy Christy, H. (2024). Utilizing oncomir and tsmir as biomarkers for screening breast cancer. Current Trends in Biotechnology and Pharmacy, 18(Supplementry Issue 4A), 18–30. 10.5530/ctbp.2024.4s.2
Hammond, S. M. (2015). An overview of microRNAs. Adv Drug Deliv Rev, 87, 3–14. 10.1016/j.addr.2015.05.001
Hartmann, P., and Tacke, F. (2016). Tiny RNA with great effects: miR-155 in alcoholic liver disease. Journal of Hepatology, 64, 1214–1216. http://dx.doi.org/10.1016/j.jhep.2016.01.035
Hayes, J., Peruzzi, P. P. and Lawler, S. (2014). MicroRNAs in cancer: biomarkers, functions and therapy. Trends in molecular medicine, 20(8), 460-469. 10.1016/j.molmed.2014.06.005
He, b., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., Xie, H., Peng, X., Yin, W., Tao, Y., and Wang, X. (2020). miRNA-based biomarkers, therapies, and resistance in cancer. International Journal of Biological Sciences, 16(14), 2628− 2647. 10.7150/ijbs.47203
Hussen, B. M., Hidayat, H. J., Salihi, A., Sabir, D. K., Mohammad Taheri, M., and Ghafouri-Fard, S. (2021). MicroRNA: A signature for cancer progression. Biomedicine & Pharmacotherapy, 138, 1−11. https://doi.org/10.1016/j.biopha.2021.111528
Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S. and Ménard, S. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer research, 65(16), 7065-7070. 10.1158/0008-5472.CAN-05-1783
Jia, C. Y., Li, H. H., Zhu, X. C., Dong, Y. W., Fu, D., Zhao, Q. L., Wu, W., Wu, X. Z. (2011). MiR-223 Suppresses Cell Proliferation by Targeting IGF-1R. PloS one, 6(11), 1-13. 10.1371/journal.pone.0027008
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A. and Slack, F. J. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635-647. 10.1016/j.cell.2005.01.014
Karagün, B. Ş., Antmen, B., Şaşmaz, İ. and Kılınç, Y. (2014). Mikro RNA and Cancer. Türk Klinik Biyokimya, 12(1), 45-56. Kim, K., Chadalapaka, G., Lee, S. O., Yamada, D., Sastre-Garau, X., Defossez, P. A., Park, Y. Y., Lee, J. S., and Safe, S. (2012). Identification of oncogenic microRNA-17–92/ZBTB4/specificity protein axis in breast cancer. Oncogene, 31(8), 1034–1044. 10.1038/onc.2011.296
Kozomara, A., Birgaoanu, M. and Griffiths-Jones, S. (2019). miRBase: from microRNA sequences to function. Nucleic acids research, 47(D1), D155-D162. https://doi.org/10.1093/nar/gky1141
Lee, R. C., Feinbaum, R. L., Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 843-854. 10.1016/0092-8674(93)90529-y
Li, S., Yang, C., Zhai, L., Zhang, W., Yu, J., Gu, F., Lang, R., Fan, Y., Gong, M., Zhang, X., and Fu, L. (2012). Deep sequencing reveals small RNA characterization of invasive micropapillary carcinomas of the breast. Breast Cancer Res Treat, 136(1), 77–87. 10.1007/s10549-012-2166-6
Li, Y Zhang, L., Dong, Z., Xu, H., Yan, L., Wang, W., Yang, Q., and Chen, C. (2021). MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer. Pathology - Research and Practice, 220, 1-11. https://doi.org/10.1016/j.prp.2021.153405
Lima, T. I., Araujo, H. N., Menezes, E. S., Sponton, C.H., Araujo, M. B., Bomfim, L. H. M., Queiroz, A. L., Passos, M. A., Sousa, T. A. E., Hirabara, S. M., Martins, A.R., Sampaio, H. C. L. B., Rodrigues, A., Curi, R., Carneiro, E. M., Boschero, A. C., and Silveira, L. R. (2017). Role of microRNAs on the regulation of mitochondrial biogenesis and insulin signaling in skeletal muscle. Journal of cellular physiology, 232(5), 958-966. 10.1002/jcp.25645
Lin, T., Dong, W., Huang, J., Pan, Q., Fan, X., Zhang, C. and Huang, L. (2009). MicroRNA-143 as a tumor suppressor for bladder cancer. The Journal of urology, 181(3), 1372-1380. 10.1016/j.juro.2008.10.149
Lu, T. X. and Rothenberg, M. E. (2018). MicroRNA. Journal of Allergy and Clinical Immunology, 141(4), 1202-1207. 10.1016/j.jaci.2017.08.034
Lukman Anwar, S., Tanjung, D. S., Fitria, M. S., Kartika, A. I., Indah Sari, D. N., Dinna Rakhmina, D., Wardana, T., Astuti, I., Haryana, S. M., and Aryandono, T. (2020). Dynamic changes of circulating Mir-155 expression and the potential application as a non-invasive biomarker in breast cancer. Asian Pacific Journal of Cancer Prevention, 21, 491– 497. 10.31557/APJCP.2020.21.2.491
Ma, Y., Bu, D., Long, J., Chai, W., and Dong, J. (2019). LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. Journal of Cellular Physiology, 234(3), 2880–2894. 10.1002/jcp.27105 MacFarlane, L. A., and Murphy, P. R. (2010). MicroRNA: biogenesis, function and role in cancer. Current genomics, 11(7), 537-561. 10.2174/138920210793175895
McCaffrey, A. P., Meuse, L., Pham, T. T. T., Conklin, D. S., Hannon, G. J. and Kay, M. A. (2002). RNA interference in adult mice. Nature, 418(6893), 38-39. 10.1038/418038a
Meier, J., Hovestadt, V., Zapatka, M., Pscherer, A., Lichter, P., and Seiffert, M. (2013). Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP. RNA Biology, 10(6), 1017-1029. 10.4161/rna.24553
miRBase (2024). World Food Programme, http://mirbase.org/ (Accessed date: 01 March 2025).
Mishra, S., Yadav, T., and Rani, V. (2016). Exploring miRNA based approaches in cancer diagnostics and therapeutics. Critical Reviews in Oncology/Hematology, 98, 12–23. http://dx.doi.org/10.1016/j.critrevonc.2015.10.003
Mott, J. L., Kobayashi, S., Bronk, S. F. and Gores, G. J. (2007). mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene, 26(42), 6133-6140. 10.1038/sj.onc.1210436
Mraz, M., Dolezalova, D., Plevova, K., Kozubik, K. S., Mayerova, V., Cerna, K., Musilova, K., Tichy, B., Pavlova, S., Borsky, M., Verner, J., Doubek, M., Brychtova, Y., Trbusek, M., Hampl, A., Mayer, J., and Pospisilova, S. (2012). MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood, 119(9), 2110-2113. 10.1038/418038a
Musilová, K., and Mráz, M. (2015). MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia, 29(5), 1004-1017. 10.1038/leu.2014.351
Otmani, K., and Lewalle, P. (2021). Tumor suppressor miRNA in Cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front. Oncol, 11, 1–15. 10.3389/fonc.2021.708765
Rothschild, S. I. (2014). microRNA therapies in cancer. Molecular and cellular therapies, 2(7), 1-8. https://doi.org/10.1186/2052-8426-2-7
Saffar, K. N., Larypoor, M. and Torbati, M. B. (2024). Analyzing of colorectal cancerrelated genes and microRNAs expression profiles in response to probiotics Lactobacillus acidophilus and Saccharomyces cerevisiae in colon cancer cell lines. Molecular Biology Reports, 51(1), 1-14. https://doi.org/10.1007/s11033-023-09008-w
Salehi, M., Kamali, M. J., Arab, D., Safaeian, N., Ashuori, Z., Maddahi, M., Latifi, N., and Jahromi, A. M. (2024). Exosomal microRNAs in regulation of tumor cells resistance to apoptosis. Biochemistry and Biophysics Reports, 37, 1-14. https://doi.org/10.1016/j.bbrep.2024.101644
Smolarz, B., Durczy ´nski, A., Romanowicz, H., Szyłło, K., and Hogendorf, P. (2022). miRNAs in cancer (review of literature). Int. J. Mol. Sci., 23, 1−18. https://doi.org/10.3390/ijms23052805
Stankevicins, L., Barat, A., Dessen, P., Vassetzky, Y., and de Moura Gallo, C. V. (2017). The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model. PLoS One, 12(3), e0173756. 10.1371/journal.pone.0173756
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H. and Mitsudomi, T. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer research, 64(11), 3753-3756. 10.1158/0008-5472.CAN-04-0637
Tan, S., Ding, K., Chong, Q. Y., Zhao, J., Liu, Y., Shao, Y., Yuanyuan Zhang, Y., Yu, Q., Xiong, Z., Zhang, W., Zhang, M., Li, G., Li, X., Kong, X., Ahmad, A., Wu, Z., Wu, Q., Zhao, X., E Lobie, P. E., and Zhu, T. (2017). Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptorpositive breast cancer cells. Journal of Biological Chemistry, 292(33), 13551–13564. 10.1074/jbc.M117.780973
Taniguchi, K., Wada, S. I., Ito, Y., Hayashi, J., Inomata, Y., Lee, S. W., Tanaka, T., Komura, K., Akao, Y., Urata, H., and Uchiyama, H. (2019). Tumor α‑aminoisobutyric acid-containing amphipathic helical peptide- cyclic RGD conjugation as a potential drug delivery system for microRNA replacement therapy in vitro. Molecular Pharmaceutics, 16, 4542−4550. 10.3389/fonc.2021.708765
Ward, A., Shukla, K., Balwierz, A., Soons, Z., Konig, R., Sahin, O., and Wiemann, S. (2014). MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. The Journal of Pathology, 233(4), 368–379. 10.1002/path.4363
Winter, J., Jung, S., Keller, S., Gregory, R. I., and Diederichs, S. (2009). Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature cell biology, 11(3), 228-234. 10.1038/ncb0309-228
Wu, Q., Wang, C., Lu, Z., Guo, L., and Ge, Q. (2012). Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim. Acta, 413(13-14), 1058–1065. 10.1016/j.cca.2012.02.016
Yang, W., Gu, J., Wang, X., Wang, Y., Feng, M., Zhou, D., Guo, M., and Zhou, M. (2019). Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7. Journal of Cellular and Molecular Medicine, 23(5), 3166–3177. 10.1111/jcmm.14171
Zhang, C. M., Zhao, J., and Deng, H. Y. (2013). MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. Journal of Biomedical Science, 20, 1–10. http://www.jbiomedsci.com/content/20/1/79

Details

Primary Language

English

Subjects

Gene Expression, Genomics, Genetics (Other)

Journal Section

Other

Authors

Faten Alnoaimi ^*
0000-0003-2140-8681
Türkiye

Mehmet Özaslan
0000-0001-9380-4902
Türkiye

Early Pub Date

August 1, 2025

Publication Date

August 1, 2025

Submission Date

April 21, 2025

Acceptance Date

June 3, 2025

Published in Issue

Year 2025 Volume: 6 Number: 3

DOI

https://doi.org/10.55549/zbs.1680820

IZ

https://izlik.org/JA78CH53ZG

APA

Alnoaimi, F., & Özaslan, M. (2025). Cancer Prognosis and miRNA. Zeugma Biological Science, 6(3), 1-14. https://doi.org/10.55549/zbs.1680820

AMA

1.Alnoaimi F, Özaslan M. Cancer Prognosis and miRNA. zbs. 2025;6(3):1-14. doi:10.55549/zbs.1680820

Chicago

Alnoaimi, Faten, and Mehmet Özaslan. 2025. “Cancer Prognosis and MiRNA”. Zeugma Biological Science 6 (3): 1-14. https://doi.org/10.55549/zbs.1680820.

EndNote

Alnoaimi F, Özaslan M (August 1, 2025) Cancer Prognosis and miRNA. Zeugma Biological Science 6 3 1–14.

IEEE

[1]F. Alnoaimi and M. Özaslan, “Cancer Prognosis and miRNA”, zbs, vol. 6, no. 3, pp. 1–14, Aug. 2025, doi: 10.55549/zbs.1680820.

ISNAD

Alnoaimi, Faten - Özaslan, Mehmet. “Cancer Prognosis and MiRNA”. Zeugma Biological Science 6/3 (August 1, 2025): 1-14. https://doi.org/10.55549/zbs.1680820.

JAMA

1.Alnoaimi F, Özaslan M. Cancer Prognosis and miRNA. zbs. 2025;6:1–14.

MLA

Alnoaimi, Faten, and Mehmet Özaslan. “Cancer Prognosis and MiRNA”. Zeugma Biological Science, vol. 6, no. 3, Aug. 2025, pp. 1-14, doi:10.55549/zbs.1680820.

Vancouver

1.Faten Alnoaimi, Mehmet Özaslan. Cancer Prognosis and miRNA. zbs. 2025 Aug. 1;6(3):1-14. doi:10.55549/zbs.1680820

Cancer Prognosis and miRNA

Abstract

Keywords

Supporting Institution

Ethical Statement

References

Details

Primary Language

Subjects

Journal Section

Authors

Early Pub Date

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite